Decimmune Therapeutics' Series A Round

Decimmune Therapeutics raised a round of funding on October 13, 2006.

DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's a…

Articles about Decimmune Therapeutics' Series A Round: